Drug intelligence / Profile preview

emilumenib

Development stage: Phase 2
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral

Overview

Emilumenib is an orally available small-molecule menin inhibitor developed by Daiichi Sankyo Co., Ltd. It functions by binding to the nuclear protein menin (MEN1) and preventing its interaction with the menin-mixed lineage leukemia (MLL; KMT2A, lysine methyltransferase 2A) complex. This disruption of the menin-KMT2A interaction inhibits proleukemogenic signaling, leading to the differentiation and apoptosis of leukemic cells. Emilumenib is being investigated for the treatment of acute leukemias, specifically acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), particularly in cases with KMT2A rearrangements or NPM1 mutations.

Other names: emilumenib succinate

Targets

MEN1 (Menin)

Beyond the preview

Go deeper on emilumenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on emilumenib.

Explore the full profile